Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Pharma Co., Ltd.

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

AI in Pharma: Discovery

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

Sumitomo Pharma Co., Ltd. focuses on developing pharmaceutical products, regenerative medicine, and non-pharmaceutical solutions, with a priority on Psychiatry & Neurology and Oncology areas. The company aims to contribute to global healthcare.

Metric
Company Name	Sumitomo Pharma Co., Ltd.	AI in Pharma: Discovery	Poxel SA	Prenosis
Symbol	4.51K
MSH ID	COM:SUMITOMO-PHARMA	COM:AIINPHARMA-DISCOVERY	COM:POXEL	COM:PRENOSIS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Biotechnology	Biotechnology
Country	JP	US	FR	US
Stage			Post-IPO Debt	Grant
Employee Count	4.98K
Website	sumitomo-pharma.com/index.html	aiinpharma-discovery.com	poxel.com	prenosis.com
LinkedIn			poxel	prenosis
Founders

Metric
Market Cap	1.08B
Enterprise Value
Monthly Web Traffic		4.88K	1.15K
Web Traffic Growth		-0.63	46.92
Valuation
Raised Capital		50M	4.80M

Metric
Revenue	2.10B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.25B
EBITDA	-2.11B
Operating Income	-2.36B
Net Income	-2.10B
EPS	-5.29
Diluted EPS	-5.29
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.60
Operating Profit Margin	-0.54
EBITDA Margin	-1.01
Net Profit Margin	-0.53
Return on Equity	-0.44
Return on Assets	-0.16
Return on Capital Employed	-0.28

4506

COM:SUMITOMO-PHARMA

Sumitomo Pharma Co., Ltd.

Last Close

609.00

25/11 06:45

Market Cap

162.09B

Beta: -

Volume Today

2.30M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.77
P/B Ratio	0.39
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.82
EV Multiple	2.37

Metric
Days Sales Outstanding	107.53
Days Payables Outstanding	138.96
Days Inventory Outstanding	332.63
Operating Cycle	445.46
Cash Conversion Cycle	263.92
Asset Turnover	0.38

Metric
Operating Cash Flow	-1.61B
Free Cash Flow	-1.72B
Cash Flow to Debt	-0.35
Operating Cash Flow/Sales	-0.42
Free Cash Flow Yield	-2.16

Metric
Cash & Equivalents	193.72M
Accounts Receivable	156.00M
Inventory	769.31M
Goodwill	1.33B
Debt to Capitalization	0.73
Debt to Assets	0.39
Current Ratio	0.63
Quick Ratio	0.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.39
SG&A to Revenue	0.83